Remember
 
 
At SpeculatingStocks You Can Discover Stocks, Post Anonymously, and React to Posts. Login is Optional.
Watch for Reactions to Your Posts or React Below to Other's Posts. Discover Stocks and Market Data.

Biotech Stocks & ETFs, Headlines, and Posts Bucket Watchlist of Biotech Stocks, ETFs, Headlines and Posts

Types of Stocks and ETFs: biotech, biotechnology, biopharma, pharma, etc.















Watchlist of Stocks and ETFs Based on Theme: Companies Related to Biotech.

Generated with SpeculatingStocks Stock Theme Analytics Algorithmâ„¢ - More Bucket Watchlists of Stocks.

Important Note: Most of the stocks and ETFs in this list directly relate to biotech; however, a few may just somewhat depend and/or be indirectly related to biotech. As always complete your own due diligence.


Biotech Stocks & ETFs


Symbol
Company / ETF Name
Market Cap













































































































































































































































N/AN/A

10/22/2017: RedHill Biopharma Receives FDA Orphan Drug Designation for MESUPRON for Pancreatic Cancer



10/18/2017: Gritstone Oncology and Arbutus Biopharma Announce LNP Technology Licensing Agreement to Develop Novel RNA-Based Personal...



10/18/2017: Health insurer Anthem takes pharmacy business in house, taps CVS to help



10/17/2017: Stocks to Watch: Kite Pharma, Expedia, IXYS, Amazon, Vulcan Materials, CBS



10/16/2017: Biotech, pharma shares drop after Trump says 'drug prices are out of control'



10/14/2017: Intellipharmaceutics Announces Closing of US$4 Million Financing



10/13/2017: Arbutus to Participate in Upcoming Investor Conferences



10/13/2017: Theravance Biopharma Reports Positive New Data from Multiple Studies of VIBATIV(R) (telavancin) at IDWeek(TM) 2017



10/13/2017: Gene Therapy Is Nearing a Major Breakthrough



10/13/2017: RedHill Biopharma to Present at the BioNetwork 2017 Partnering Summit



10/13/2017: Intellipharmaceutics Announces US$4 Million Registered Direct Offering



10/13/2017: Breakfast Technical Briefing on Biotech Stocks -- Dynavax Technologies, Keryx Biopharma, Moleculin Biotech, and ZIOPHARM...



10/13/2017: Credit Suisse reveals its top biotech stock picks ahead of earnings



10/13/2017: Keryx Biopharmaceuticals Announces Presentations of New Data at the American Society of Nephrology Kidney Week 2017 Annu...



10/12/2017: Breakfast Technical Briefing on Biotech Stocks -- Dynavax Technologies, Keryx Biopharma, Moleculin Biotech, and ZIOPHARM...



10/10/2017: Favorite stock picks from one of Wall Street's top biotech analysts



10/08/2017: Press Release: RedHill Biopharma Announces Positive Top-Line Results from Phase II Study of BEKINDA(R) in Patients with ...



10/03/2017: SELLAS Enters into a Clinical Trial Collaboration and Supply Agreement with Merck & Co., Inc., Kenilworth, N.J., USA



10/02/2017: Hemispherx Biopharma Files 8K - Changes Exec Mgmt



10/02/2017: XTL Biopharmaceuticals Reports First Half 2017 Financial Results & Provides Clinical and Operational Update



09/30/2017: Cher is suing an LA billionaire and Florida health care company over biopharmaceutical investment



09/30/2017: EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Intellipharmaceutics Internatio...



09/29/2017: A biotech stock just instantly doubled in value on positive epilepsy drug test results



09/29/2017: Galena Biopharma Announces Completion of Enrollment in Two NeuVax(TM) (nelipepimut-S) Clinical Trials in Combination wit...



09/26/2017: Navidea Biopharmaceuticals to Present at the Rodman & Renshaw 19(th) Annual Global Investment Conference



09/26/2017: ARCA biopharma to Present at the Sidoti & Company Fall 2017 Conference



09/23/2017: RedHill Biopharma Receives Notice of Allowance for a New U.S. Patent Covering its Combination Therapy for Hard-to-Treat ...



09/22/2017: Traders expect an 80% move for this hot biotech stock in the next month



09/20/2017: Takeda CEO Prescribes Stability After Rough Start



09/08/2017: Forget casinos: This Native American tribe is doing business in pharma patents



09/04/2017: We want to globalize our products and our company, Takeda Pharmaceutical CEO says




Recent Biotech Posts (Pulses)




10/23/2017: $BNIKF (Benitec Biopharma Limited) is up more than 5%, reaching a new upside threshold. -- Go to this Pulse Post



10/23/2017: $ABIO (ARCA biopharma, Inc.) is up more than 5%, reaching a new upside threshold. -- Go to this Pulse Post



10/23/2017: $ABIO (ARCA biopharma, Inc.) has significant institutional ownership of at least 20% with institutional ownership of 29.86%. -- Go to this Pulse Post



10/23/2017: $RDHL RedHill Biopharma received notice of allowance for a new U.S. patent covering RHB-104 for relapsing-remitting multiple sclerosis. -- Go to this Pulse Post



10/23/2017: $EVOK Evoke Pharma announced 'positive' topline results from its comparative exposure pharmacokinetic study; co will submit a 505(b)(2) NDA with a selected Gimoti dose to the FDA in 1Q18. -- Go to this Pulse Post



10/22/2017: $RDHL (RedHill Biopharma Ltd.) is up more than 5%, reaching a new upside threshold. -- Go to this Pulse Post



10/20/2017: $RDHL RedHill Biopharma confirmed the FDA granted MESUPRON Orphan Drug designation for the adjuvant treatment of pancreatic cancer. -- Go to this Pulse Post



10/19/2017: $NEXS (Nexus Biopharma, Inc.) is up more than 20%, reaching a new upside threshold. -- Go to this Pulse Post



10/19/2017: $BNTC (Benitec Biopharma LTD) is down more than 5%, reaching a new downside threshold. -- Go to this Pulse Post



10/18/2017: $ABUS Arbutus Biopharma announced a collaboration and license agreement w/ Gritstone Oncology. -- Go to this Pulse Post



10/18/2017: $BNTC Benitec Biopharma announced issuance of new patent relating to its hepatitis B program in the US. -- Go to this Pulse Post



10/18/2017: $SBFM (Sunshine Biopharma, Inc.) is down more than 10%, reaching a new downside threshold. -- Go to this Pulse Post



10/17/2017: $BNIKF (Benitec Biopharma Limited) is up more than 20%, reaching a new upside threshold. -- Go to this Pulse Post



10/17/2017: $NAVB (Navidea Biopharmaceuticals, Inc) is trading at a trailing PE of less than 25 with a Price to Earnings ratio of only 0.91. -- Go to this Pulse Post



10/16/2017: $XBI Biotech stocks give up gains after Trump reaffirmed criticism of drug priced -- saying pharma is 'getting away with murder'. -- Go to this Pulse Post



10/15/2017: $NAVB (Navidea Biopharmaceuticals, Inc) is trading at a trailing PE of less than 25 with a Price to Earnings ratio of only 0.89. -- Go to this Pulse Post



10/13/2017: $SNNA (Sienna Biopharmaceuticals Inc.) is cash flow positive as of at least the last quarter with Quarterly Cash Flow of $24.95M. -- Go to this Pulse Post



10/13/2017: $SNNA (Sienna Biopharmaceuticals Inc.) did not produce a profit last quarter with Quarterly Net Income of $(12.86M). -- Go to this Pulse Post



10/13/2017: $NEXS (Nexus Biopharma, Inc.) is down more than 20%, reaching a new downside threshold. -- Go to this Pulse Post



10/13/2017: $BNTCW (Benitec Biopharma Limited) is up more than 50%, reaching a new upside threshold. -- Go to this Pulse Post



10/13/2017: $BNTC (Benitec Biopharma LTD) is significantly more volatile than the overall market with a Beta of 3.60. -- Go to this Pulse Post



10/13/2017: $TBPH (Theravance Biopharma, Inc.) is significantly more volatile than the overall market with a Beta of 2.07. -- Go to this Pulse Post



10/13/2017: $TBPH (Theravance Biopharma, Inc.) could become a potential short squeeze opportunity with significant short interest of 42.88%. -- Go to this Pulse Post



10/13/2017: $TBPH (Theravance Biopharma, Inc.) has significant institutional ownership of at least 20% with institutional ownership of 82.95%. -- Go to this Pulse Post



10/13/2017: $HEB (Hemispherx Biopharma, Inc.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.92. -- Go to this Pulse Post



10/13/2017: $ALDR (Alder Biopharmaceuticals Inc.) could become a potential short squeeze opportunity with significant short interest of 18.46%. -- Go to this Pulse Post



10/13/2017: $ALDR (Alder Biopharmaceuticals Inc.) has significant institutional ownership of at least 20% with institutional ownership of 89.24%. -- Go to this Pulse Post



10/13/2017: $SBMFF (Sino Biopharmaceutical Ltd.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.83. -- Go to this Pulse Post



10/13/2017: $SBMFF (Sino Biopharmaceutical Ltd.) is trading at a P/S of at or below sales with a Price to Sales ratio of only 0.52. -- Go to this Pulse Post



10/13/2017: $INBP (Integrated Biopharma Inc.) is trading at a P/S of at or below sales with a Price to Sales ratio of only 0.09. -- Go to this Pulse Post



10/13/2017: $BNIKF (Benitec Biopharma Limited) is down more than 10%, reaching a new downside threshold. -- Go to this Pulse Post



10/13/2017: $BNIKF (Benitec Biopharma Limited) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.98. -- Go to this Pulse Post



10/13/2017: $RDHL (RedHill Biopharma Ltd.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.87. -- Go to this Pulse Post



10/13/2017: $RDHL (RedHill Biopharma Ltd.) has significant institutional ownership of at least 20% with institutional ownership of 24.47%. -- Go to this Pulse Post



10/13/2017: $GALE (Galena Biopharma, Inc.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.76. -- Go to this Pulse Post



10/13/2017: $GALE (Galena Biopharma, Inc.) is significantly more volatile than the overall market with a Beta of 2.33. -- Go to this Pulse Post



10/13/2017: $GALE (Galena Biopharma, Inc.) could become a potential short squeeze opportunity with significant short interest of 10.58%. -- Go to this Pulse Post



10/13/2017: $GALE (Galena Biopharma, Inc.) has significant institutional ownership of at least 20% with institutional ownership of 25.96%. -- Go to this Pulse Post



10/13/2017: $NAVB (Navidea Biopharmaceuticals, Inc) is trading at a trailing PE of less than 25 with a Price to Earnings ratio of only 0.90. -- Go to this Pulse Post



10/13/2017: $KERX (Keryx Biopharmaceuticals Inc.) could become a potential short squeeze opportunity with significant short interest of 19.67%. -- Go to this Pulse Post



10/13/2017: $KERX (Keryx Biopharmaceuticals Inc.) has significant institutional ownership of at least 20% with institutional ownership of 63.66%. -- Go to this Pulse Post



10/13/2017: $HEB (Hemispherx Biopharma, Inc.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.94. -- Go to this Pulse Post



10/12/2017: $INBP (Integrated Biopharma Inc.) is trading at a trailing PE of less than 25 with a Price to Earnings ratio of only 2.84. -- Go to this Pulse Post



10/12/2017: $AVXL Anavex announced pharmacokinetic (PK) and pharmacodynamic (PD) data for ANAVEX2-73 from its positive Phase 2a study in mild-to-moderate Alzheimer's disease patients. -- Go to this Pulse Post



10/11/2017: $SBBP (Strongbridge Biopharma plc) has significant institutional ownership of at least 20% with institutional ownership of 79.97%. -- Go to this Pulse Post



10/11/2017: $IPCI Intellipharmaceutics Intl to sell 3,636,364 common shares at a purchase price of $1.10 per share in a registered direct offering. -- Go to this Pulse Post



10/11/2017: $SLNO Soleno Therapeutics issued new U.S. patent (9,782,416) related to the use of pharmaceutical formulations of diazoxide to treat hyperphagia in a subject with Prader-Willi syndrome. -- Go to this Pulse Post



10/10/2017: $NAVB (Navidea Biopharmaceuticals, Inc) is trading at a trailing PE of less than 25 with a Price to Earnings ratio of only 0.87. -- Go to this Pulse Post



10/10/2017: $ALDR (Alder Biopharmaceuticals Inc.) is significantly more volatile than the overall market with a Beta of 2.13. -- Go to this Pulse Post



10/10/2017: $ALDR (Alder Biopharmaceuticals Inc.) has significant institutional ownership of at least 20% with institutional ownership of 90.26%. -- Go to this Pulse Post



10/09/2017: $TBPH Theravance Biopharma announced 'positive' new data from multiple studies of VIBATIV (telavancin) were presented at IDWeek, which was held in San Diego, CA on October 4 - 8, 2017. -- Go to this Pulse Post



10/08/2017: $SBFM (Sunshine Biopharma, Inc.) is down more than 10%, reaching a new downside threshold. -- Go to this Pulse Post



10/08/2017: $INBP (Integrated Biopharma Inc.) is down more than 5%, reaching a new downside threshold. -- Go to this Pulse Post



10/06/2017: $NAVB (Navidea Biopharmaceuticals, Inc) is trading at a trailing PE of less than 25 with a Price to Earnings ratio of only 0.91. -- Go to this Pulse Post



10/06/2017: $ABIO (ARCA biopharma, Inc.) has significant institutional ownership of at least 20% with institutional ownership of 29.88%. -- Go to this Pulse Post



10/05/2017: $BNTC (Benitec Biopharma LTD) is down more than 5%, reaching a new downside threshold. -- Go to this Pulse Post



10/04/2017: $SBBP Strongbridge Biopharma commenced public offering of ordinary shares. -- Go to this Pulse Post



10/04/2017: $SBFM (Sunshine Biopharma, Inc.) is up more than 10%, reaching a new upside threshold. -- Go to this Pulse Post



10/04/2017: $SBBP (Strongbridge Biopharma plc) is down more than 10%, reaching a new downside threshold. -- Go to this Pulse Post



10/04/2017: $SBBP Strongbridge Biopharma priced 4M common shares at $6.25 per share. -- Go to this Pulse Post



10/03/2017: $RDHL (RedHill Biopharma Ltd.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.9. -- Go to this Pulse Post



10/03/2017: $KERX (Keryx Biopharmaceuticals Inc.) could become a potential short squeeze opportunity with significant short interest of 21.95%. -- Go to this Pulse Post



10/03/2017: $KERX (Keryx Biopharmaceuticals Inc.) has significant institutional ownership of at least 20% with institutional ownership of 63.39%. -- Go to this Pulse Post



10/03/2017: $GALE (Galena Biopharma, Inc.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.77. -- Go to this Pulse Post



10/03/2017: $GALE (Galena Biopharma, Inc.) has significant institutional ownership of at least 20% with institutional ownership of 26.65%. -- Go to this Pulse Post



10/03/2017: $SBBP Strongbridge Biopharma commenced public offering of ordinary shares. -- Go to this Pulse Post



10/03/2017: $TBPH Theravance Biopharma to present new studies of VIBATIV (telavancin) at IDWeek 2017. -- Go to this Pulse Post



10/03/2017: $RDHL RedHill Biopharma announced positive top-line results from the Phase II clinical study of BEKINDA 12 mg for the treatment of diarrhea-predominant irritable bowel syndrome (shares halted. -- Go to this Pulse Post



10/02/2017: $HEB (Hemispherx Biopharma, Inc.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.88. -- Go to this Pulse Post



10/02/2017: $RDHL RedHill Biopharma accelerates the timelines for the ongoing first Phase III study with RHB-104 for Crohn's disease by curtailing the number of subjects planned to be enrolled in the study from 410 to approx. 325 subjects. -- Go to this Pulse Post



10/02/2017: $ABUS Arbutus Biopharma signed a share purchase agreement with Roivant Sciences for the sale of $116.4M of convertible preferred shares. -- Go to this Pulse Post



10/02/2017: $GALE Galena Biopharma's merger partner Sellas Life Sciences entered into a Clinical Trial Collaboration and Supply Agreement for the conduct of a combination clinical trial targeting multiple cancer types with Merck (MRK. -- Go to this Pulse Post



10/02/2017: $INBP (Integrated Biopharma Inc.) is trading at a trailing PE of less than 25 with a Price to Earnings ratio of only 2.96. -- Go to this Pulse Post



10/02/2017: $GALE (Galena Biopharma, Inc.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.71. -- Go to this Pulse Post



10/01/2017: $XTLB (XTL Biopharmaceuticals Ltd.) did not produce a profit last quarter with Quarterly Net Income of $(4.98M). -- Go to this Pulse Post



09/29/2017: $ABUS (Arbutus Biopharma Corporation) has significant institutional ownership of at least 20% with institutional ownership of 98.36%. -- Go to this Pulse Post



09/29/2017: $BNTCW (Benitec Biopharma Limited) is down more than 5%, reaching a new downside threshold. -- Go to this Pulse Post



09/28/2017: $ALDR (Alder Biopharmaceuticals Inc.) could become a potential short squeeze opportunity with significant short interest of 22.08%. -- Go to this Pulse Post



09/28/2017: $GALE (Galena Biopharma, Inc.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.74. -- Go to this Pulse Post



09/28/2017: $GALE (Galena Biopharma, Inc.) could become a potential short squeeze opportunity with significant short interest of 10.78%. -- Go to this Pulse Post



09/28/2017: $GALE (Galena Biopharma, Inc.) has significant institutional ownership of at least 20% with institutional ownership of 20.41%. -- Go to this Pulse Post



09/28/2017: $SBBP (Strongbridge Biopharma plc) has significant institutional ownership of at least 20% with institutional ownership of 52.11%. -- Go to this Pulse Post



09/28/2017: There's a rumor that Amazon $AMZN may try to disrupt the $300 billion pharmacy business. An analyst at Bernstein says he "expects it." -- Go to this Pulse Post



09/27/2017: $TBPH (Theravance Biopharma, Inc.) could become a potential short squeeze opportunity with significant short interest of 42.22%. -- Go to this Pulse Post



09/27/2017: $TBPH (Theravance Biopharma, Inc.) has significant institutional ownership of at least 20% with institutional ownership of 82.62%. -- Go to this Pulse Post



09/27/2017: $BNTC (Benitec Biopharma LTD) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.89. -- Go to this Pulse Post



09/27/2017: $ALDR (Alder Biopharmaceuticals Inc.) has significant institutional ownership of at least 20% with institutional ownership of 98.05%. -- Go to this Pulse Post



09/26/2017: $ABUS (Arbutus Biopharma Corporation) is down more than 5%, reaching a new downside threshold. -- Go to this Pulse Post



09/26/2017: $RDHL (RedHill Biopharma Ltd.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.93. -- Go to this Pulse Post



09/26/2017: $KERX (Keryx Biopharmaceuticals Inc.) has significant institutional ownership of at least 20% with institutional ownership of 63.19%. -- Go to this Pulse Post



09/25/2017: $ABUS Arbutus Biopharma announced topline results of the bi-weekly dosing segment of Cohort 4 of the Phase II study of its RNAi agent, ARB-1467. -- Go to this Pulse Post



09/25/2017: $IPCI Intellipharmaceutics Intl provided update on its RexistaTM, henceforth referred to as Oxycodone Hydrochloride Extended-Release Tablets program. -- Go to this Pulse Post



09/24/2017: $NAVB (Navidea Biopharmaceuticals, Inc) is trading at a trailing PE of less than 25 with a Price to Earnings ratio of only 0.84. -- Go to this Pulse Post



09/23/2017: $GALE (Galena Biopharma, Inc.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.71. -- Go to this Pulse Post



09/23/2017: $ABUS Arbutus Biopharma indicated higher after detailing plans to present HBV Data at upcoming conferences. -- Go to this Pulse Post



09/23/2017: $ABUSArbutus Biopharma indicated higher after detailing plans to present HBV Data at upcoming conferences. -- Go to this Pulse Post



09/22/2017: $RDHL (RedHill Biopharma Ltd.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.87. -- Go to this Pulse Post



09/22/2017: $INBP (Integrated Biopharma Inc.) is trading at a P/S of at or below sales with a Price to Sales ratio of only 0.1. -- Go to this Pulse Post



09/22/2017: $INBP (Integrated Biopharma Inc.) is trading at a trailing PE of less than 25 with a Price to Earnings ratio of only 2.97. -- Go to this Pulse Post



09/21/2017: $BNTC (Benitec Biopharma LTD) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.94. -- Go to this Pulse Post



09/21/2017: $BNTC (Benitec Biopharma LTD) is significantly more volatile than the overall market with a Beta of 3.54. -- Go to this Pulse Post



09/21/2017: $HEB (Hemispherx Biopharma, Inc.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.96. -- Go to this Pulse Post



09/21/2017: $BNIKF (Benitec Biopharma Limited) is up more than 5%, reaching a new upside threshold. -- Go to this Pulse Post



09/21/2017: $TBPH (Theravance Biopharma, Inc.) is significantly more volatile than the overall market with a Beta of 2.21. -- Go to this Pulse Post



09/21/2017: $TBPH (Theravance Biopharma, Inc.) could become a potential short squeeze opportunity with significant short interest of 42.60%. -- Go to this Pulse Post



09/21/2017: $TBPH (Theravance Biopharma, Inc.) has significant institutional ownership of at least 20% with institutional ownership of 44.53%. -- Go to this Pulse Post



09/20/2017: $RDHL (RedHill Biopharma Ltd.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.86. -- Go to this Pulse Post



09/20/2017: $BNIKF (Benitec Biopharma Limited) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.79. -- Go to this Pulse Post



09/20/2017: $RDHL (RedHill Biopharma Ltd.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.87. -- Go to this Pulse Post



09/20/2017: $ABUS (Arbutus Biopharma Corporation) is up more than 10%, reaching a new upside threshold. -- Go to this Pulse Post



09/20/2017: $SBMFF (Sino Biopharmaceutical Ltd.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.77. -- Go to this Pulse Post



09/20/2017: $SBMFF (Sino Biopharmaceutical Ltd.) is trading at a P/S of at or below sales with a Price to Sales ratio of only 0.48. -- Go to this Pulse Post



09/20/2017: $SBMFF (Sino Biopharmaceutical Ltd.) is cash flow positive as of at least the last quarter with Quarterly Cash Flow of $101.12M. -- Go to this Pulse Post



09/20/2017: $SBMFF (Sino Biopharmaceutical Ltd.) is profitable as of at least the last quarter with Quarterly Net Income of $1.58B. -- Go to this Pulse Post



09/19/2017: $HEB (Hemispherx Biopharma, Inc.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.9. -- Go to this Pulse Post



09/19/2017: $ABUS (Arbutus Biopharma Corporation) is up more than 10%, reaching a new upside threshold. -- Go to this Pulse Post



09/18/2017: $NAVB (Navidea Biopharmaceuticals, Inc) is trading at a trailing PE of less than 25 with a Price to Earnings ratio of only 0.82. -- Go to this Pulse Post



09/18/2017: $ABUS (Arbutus Biopharma Corporation) is up more than 10%, reaching a new upside threshold. -- Go to this Pulse Post



09/18/2017: $SNNA (Sienna Biopharmaceuticals Inc.) is down more than 5%, reaching a new downside threshold. -- Go to this Pulse Post



09/18/2017: $HEB (Hemispherx Biopharma, Inc.) is up more than 5%, reaching a new upside threshold. -- Go to this Pulse Post



09/18/2017: $ABUS (Arbutus Biopharma Corporation) is up more than 5%, reaching a new upside threshold. -- Go to this Pulse Post



09/18/2017: $KERX (Keryx Biopharmaceuticals Inc.) is up more than 5%, reaching a new upside threshold. -- Go to this Pulse Post



09/18/2017: $INBP (Integrated Biopharma Inc.) is trading at a P/S of at or below sales with a Price to Sales ratio of only 0.09. -- Go to this Pulse Post



09/17/2017: $BNIKF (Benitec Biopharma Limited) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.93. -- Go to this Pulse Post



09/17/2017: $ABIO (ARCA biopharma, Inc.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.75. -- Go to this Pulse Post



09/17/2017: $RDHL (RedHill Biopharma Ltd.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.84. -- Go to this Pulse Post



09/17/2017: $GALE (Galena Biopharma, Inc.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.72. -- Go to this Pulse Post



09/17/2017: $GALE (Galena Biopharma, Inc.) is significantly more volatile than the overall market with a Beta of 2.31. -- Go to this Pulse Post



09/17/2017: $GALE (Galena Biopharma, Inc.) could become a potential short squeeze opportunity with significant short interest of 11.01%. -- Go to this Pulse Post



09/17/2017: $KERX (Keryx Biopharmaceuticals Inc.) could become a potential short squeeze opportunity with significant short interest of 22.27%. -- Go to this Pulse Post



09/17/2017: $ALDR (Alder Biopharmaceuticals Inc.) could become a potential short squeeze opportunity with significant short interest of 22.11%. -- Go to this Pulse Post



09/16/2017: $INBP (Integrated Biopharma Inc.) is trading at a trailing PE of less than 25 with a Price to Earnings ratio of only 2.85. -- Go to this Pulse Post



09/15/2017: $HEB (Hemispherx Biopharma, Inc.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.93. -- Go to this Pulse Post



09/15/2017: $ABUS (Arbutus Biopharma Corporation) is up more than 5%, reaching a new upside threshold. -- Go to this Pulse Post



09/14/2017: $SBMFF (Sino Biopharmaceutical Ltd.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.71. -- Go to this Pulse Post



09/14/2017: $SBMFF (Sino Biopharmaceutical Ltd.) is trading at a P/S of at or below sales with a Price to Sales ratio of only 0.45. -- Go to this Pulse Post



09/14/2017: $ABUS (Arbutus Biopharma Corporation) is up more than 5%, reaching a new upside threshold. -- Go to this Pulse Post



09/13/2017: $HEB (Hemispherx Biopharma, Inc.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.95. -- Go to this Pulse Post



09/12/2017: $RGRX (Regenerx Biopharmaceuticals Inc.) is significantly more volatile than the overall market with a Beta of 1.98. -- Go to this Pulse Post



09/12/2017: $RDHL (RedHill Biopharma Ltd.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.8. -- Go to this Pulse Post



09/12/2017: $RDHL (RedHill Biopharma Ltd.) is cash flow negative as of at least the last quarter with Quarterly Net Cash Flow of $(47.96M). -- Go to this Pulse Post



09/12/2017: $RDHL (RedHill Biopharma Ltd.) did not produce a profit last quarter with Quarterly Net Income of $(39.56M). -- Go to this Pulse Post



09/12/2017: $BNIKF (Benitec Biopharma Limited) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.9. -- Go to this Pulse Post



09/12/2017: $ALDR (Alder Biopharmaceuticals Inc.) is significantly more volatile than the overall market with a Beta of 2.21. -- Go to this Pulse Post



09/12/2017: $ABIO (ARCA biopharma, Inc.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.73. -- Go to this Pulse Post



09/10/2017: $KERX (Keryx Biopharmaceuticals Inc.) is significantly more volatile than the overall market with a Beta of 3.41. -- Go to this Pulse Post



09/10/2017: $XTLB (XTL Biopharmaceuticals Ltd.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.98. -- Go to this Pulse Post



09/09/2017: $INBP (Integrated Biopharma Inc.) is trading at a P/S of at or below sales with a Price to Sales ratio of only 0.11. -- Go to this Pulse Post



09/09/2017: $INBP (Integrated Biopharma Inc.) is cash flow negative as of at least the last quarter with Quarterly Net Cash Flow of $(64,000). -- Go to this Pulse Post



09/09/2017: $INBP (Integrated Biopharma Inc.) is profitable as of at least the last quarter with Quarterly Net Income of $1.54M. -- Go to this Pulse Post



09/09/2017: $SBMFF (Sino Biopharmaceutical Ltd.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.79. -- Go to this Pulse Post



09/09/2017: $SBMFF (Sino Biopharmaceutical Ltd.) is trading at a P/S of at or below sales with a Price to Sales ratio of only 0.5. -- Go to this Pulse Post



09/09/2017: $SBMFF (Sino Biopharmaceutical Ltd.) is profitable as of at least the last quarter with Quarterly Net Income of $898.5M. -- Go to this Pulse Post



09/09/2017: $GALE (Galena Biopharma, Inc.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.74. -- Go to this Pulse Post



09/07/2017: $RGRX (Regenerx Biopharmaceuticals Inc.) is cash flow negative as of at least the last quarter with Quarterly Net Cash Flow of $(240,477). -- Go to this Pulse Post



09/07/2017: $RGRX (Regenerx Biopharmaceuticals Inc.) is profitable as of at least the last quarter with Quarterly Net Income of $118,379. -- Go to this Pulse Post



09/07/2017: $BNIKF (Benitec Biopharma Limited) is cash flow positive as of at least the last quarter with Quarterly Cash Flow of $5.1M. -- Go to this Pulse Post



09/07/2017: $BNIKF (Benitec Biopharma Limited) did not produce a profit last quarter with Quarterly Net Income of $(2.73M). -- Go to this Pulse Post



09/07/2017: $ABUS (Arbutus Biopharma Corporation) has significant institutional ownership of at least 20% with institutional ownership of 45.58%. -- Go to this Pulse Post



09/06/2017: $ALDR (Alder Biopharmaceuticals Inc.) has significant institutional ownership of at least 20% with institutional ownership of 50.34%. -- Go to this Pulse Post



09/05/2017: $ABIO (ARCA biopharma, Inc.) has significant institutional ownership of at least 20% with institutional ownership of 30.62%. -- Go to this Pulse Post



09/03/2017: $BNTC (Benitec Biopharma LTD) is cash flow positive as of at least the last quarter with Quarterly Cash Flow of $5.1M. -- Go to this Pulse Post



09/03/2017: $BNTC (Benitec Biopharma LTD) did not produce a profit last quarter with Quarterly Net Income of $(2.73M). -- Go to this Pulse Post



09/01/2017: $SBFM (Sunshine Biopharma, Inc.) is cash flow positive as of at least the last quarter with Quarterly Cash Flow of $111,625. -- Go to this Pulse Post



09/01/2017: $SBFM (Sunshine Biopharma, Inc.) did not produce a profit last quarter with Quarterly Net Income of $(485,444). -- Go to this Pulse Post



09/01/2017: $TBPH (Theravance Biopharma, Inc.) is cash flow negative as of at least the last quarter with Quarterly Net Cash Flow of $(30.32M). -- Go to this Pulse Post



09/01/2017: $TBPH (Theravance Biopharma, Inc.) did not produce a profit last quarter with Quarterly Net Income of $(66.29M). -- Go to this Pulse Post



09/01/2017: $TBPH (Theravance Biopharma, Inc.) could become a potential short squeeze opportunity with significant short interest of 42.36%. -- Go to this Pulse Post



09/01/2017: $TBPH (Theravance Biopharma, Inc.) has significant institutional ownership of at least 20% with institutional ownership of 79.22%. -- Go to this Pulse Post